The popular weight-loss drugs known as GLP-1 receptor agonists, which were originally meant to treat diabetes, surged in ...

Optomi Professional Services (OPS) is pleased to announce the appointment of Carey Luhn as the organization's Vice President of Strategic Accounts. In this role, Luhn will be responsible for creating ...

KnowBe4, the world-renowned cybersecurity platform that comprehensively addresses human risk management, today announced it has hired Werner Wehmeyer as its new executive vice president of customer ...

Compounded semaglutide is legal, but it's not regulated in the same way as medications like Ozempic and Wegovy.

Not all growth stocks worth buying these days focus on the artificial intelligence field. There are many exciting ones in ...

As Eli Lilly ends the year with Zepbound in good supply, TD Cowen analyst Steve Scala asked CEO David Ricks if the company ...

Tirzepatide will be available at pharmacies in Ireland initially in doses of 2.5 mg and 5 mg, with availability of higher ...

We expect Lilly to continue to grow faster than the market, and model 60% 2025 Lilly GLP-1 sales growth. Lilly gained 5 points in US prescription share in 2024, and Zepbound’s 56% share of new ...

Eli Lilly on Thursday suggested that demand for its popular diabetes and weight-loss treatments was not a concern, easing investor agitation about signs of weakness in sales of the drugs. Lilly said ...

Eli Lilly stock is higher Thursday after the pharma giant beat fourth-quarter profit expectations and issued strong 2025 ...

Fred Alger Management, an investment management company, released its “Alger Spectra Fund” fourth quarter 2024 investor ...